OBJECTIVE: To determine the frequency of the gln27glu polymorphism in the b b-2 adrenoceptor gene in patients with morbid obesity. SUBJECTS: 243 patients with morbid obesity (mean body mass index 51.6) and 199 healthy blood donors. RESULTS: The same frequency, 0.42, of the glu allele was observed in both groups. Neither the incidence in obese women (0.41, n 197) compared to control women (0.43, n 61), nor that in obese men (0.44, n 46) compared to control men (0.41, n 138) was signi®cantly different. The difference in frequency between obese men and women, 0.44 vs 0.41 was not signi®cant (P 0.68). Genotype information from the families of 18 of the obese patients showed no association between the glu27 allele and BMI. CONCLUSIONS: We ®nd no evidence for a role of the glu27 variant in the b b-2 adrenoceptor gene in the development of morbid obesity.
The risk of becoming obese has a strong genetic component and this is especially the case for morbid obesity, that is a body mass index (BMI) greater than 40. 1 Although monogenic causes of obesity in humans do occur, for example leptin de®ciency, they are comparatively rare. 2 A number of candidate genes have been proposed, variation in which may contribute, in association with environmental factors, to the development of obesity. Amongst these candidate genes are the beta adrenoceptor genes, since they play an important role in the promotion of lipolysis in human adipose tissue in vivo. 3, 4 Recently, Large et al 5 reported a strong association between a common polymorphism in the b-2 adrenoceptor gene, gln27glu, and obesity in Swedish women. The relative risk of obesity associated with this polymorphism was 7 and the odds ratio 10. Glu27glu homozygotes had an average fat mass excess of 20 kg and 50% larger fat cells than controls; however, no signi®cant changes in function were found.
We have determined the frequency of this polymorphism in a group of 243 morbidly obese (mean BMI 51, min 40, max 82) patients who underwent gastric restriction surgery at the Evangelisches und Johanniter Klinikum, Dinslaken. Patients gave informed consent and the research was approved by the Ethics Commission of the A È rztekammer Hamburg. The patients were all ethnic Germans, 197 women and 46 men, of whom 41 had type 2 diabetes. As a control population, the polymorphism frequency was determined in a group of 199 healthy, ethnic German blood donors (61 women, 138 men) attending the blood transfusion centre at the University Hospital, Eppendorf, Hamburg. The blood donors were anonymous and as a consequence we were unable to obtain their BMI. As a measure of the degree of their obesity, serum leptin values were determined, using the Quantikine TM Human Leptin Immunoassay (R&D Systems Inc., Minneapolis, USA). We determined the leptin levels, before surgery, of 61 obese women and 19 obese men. The obese patients had signi®cantly higher serum leptin levels (women 60.6 ngaml (s.d. 22.8) and men 32.3 ngaml (s.d. 13.7)) compared with the controls (women 18.3 ngaml (s.d. 12.8), men 6.5 ngaml (s.d. 4.2)).
DNA was extracted from 10 ml EDTA blood using standard methods. Genotypes were determined using the PCR-RFLP method of Large et al. 5 The genotype distribution is shown in Table 1 . The allele frequencies, both within the morbid obese patients and the blood donor controls, were in Hardy ± Weinberg equilibrium. In contrast to the ®nding of Large et al, 5 the frequency of the glu27 allele, 0.42, was the same for both morbid obese patients and for the blood donor controls. There was no signi®cant difference in the frequency between obese women and obese men, 0.41 vs 0.44, or between control women and control men, 0.43 vs 0.41. There was no signi®cant difference in the frequency of the glu27 allele between obese women and control women, 0.41 vs 0.43, nor between obese and control men, 0.44 vs 0.41. Removal of the morbid obese patients with diabetes from the analysis did not alter these ®ndings (obese 0.43, controls 0.42). There was no signi®cant difference in the mean BMI between patients who were gln27 homozygotes, gln27glu heterozygotes or glu27 homozygotes, namely 51, 52, and 50, respectively.
Genotype information was obtained from 18 families (63 individuals) of the obese patients. Eight probands were gln27 homozygotes, seven were gln27 heterozygotes and three were glu27 homozygotes. In none of the families was there any association between the polymorphism and BMI.
The reason for the discrepancy in allele frequencies between the German and Swedish populations is not clear. It may be that this association is only found in the Swedish population. Alternatively, the difference may re¯ect the fact that the patients investigated here were massively obese (mean BMI 51), whereas the Swedish women were less obese (mean BMI 39), and therefore the genetic origins of the obesity may well be different. In a recently published study of Danish men with early-onset obesity, Echwald et al 6 were also unable to show an association of the gln27glu polymorphism with obesity. The frequency of the glu27 allele in obese Danes was 0.41, and it was 0.40 in lean Danes. That obese and lean Germans, obese and lean Danes and obese Swedes had glu27 allele frequencies of 0.41, 0.40, 0.42, 0.42 and 0.48, respectively, whereas the lean Swedes had a glu27 allele frequency of 0.30, suggests that the Swedish control group had an unusually low glu27 allele frequency. In fact, there were only two glu27 homozygotes rather than the ®ve predicted by the Hardy ± Weinberg law. Further studies will reveal whether there are ethnic differences or whether the discrepancies are the result of low sample number. In a recent paper, Meirhaeghe et al 7 reported that, amongst a representative sample of Frenchmen who were gln27gln homozygotes, those that were physically inactive were signi®cantly more obese than those who regularly took physical activity, suggesting that physical activity may counterbalance the effect of a genetic predisposition to gain weight. 
